Notably, inhibition of GSK3 by Celecoxib promoted the degradation of c-FLIP and death receptor-induced apoptosis, suggesting that GSK3 might stabilize c-FLIP and antagonized tumor resistance to TRAIL33. Here, CFLAR is linked to neoplasm.